Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2010

View Archived Issues

EpiCept's crolibulin enters phase I/II trial in anaplastic thyroid cancer

Preliminary phase I data presented on TAK-285 in advanced cancer

ABT-806 enters phase I trial in EGFR-expressing advanced solid tumors

Serodus licenses RO-1160367 from Roche

Trophos to lead MitoCare consortium to study cardioprotective agent TRO-40303

Ocera Therapeutics completes two studies of OCR-002

AstraZeneca divulges novel ligands of androgen receptor

New HIV integrase inhibitors discovered at Boehringer Ingelheim

ACY-1215/bortezomib combination shows promise in models of multiple myeloma

Preclinical study in MM shows activity of GNE-652 and synergism with GDC-0941

Selective JAK-2 inhibitor BMS-911543 enters clinic as myelofibrosis therapy

Tivozanib/paclitaxel combination is well tolerated by patients with metastatic breast cancer

Xention's new company Provesica to handle OAB program

Lundbeck, Zenobia and Vernalis to codevelop dardarin inhibitors

Ipsen discontinues development of BIM-23A760

New diaza heterocyclic agents identified at Mallinckrodt

Adimab to collaborate with Lilly, Genentech and Human Genome Sciences

E.C. approves sunitinib malate for treatment of pancreatic neuroendocrine tumors

Novartis withdraws application to extend Zometa indication in E.U.

Palau Pharma begins phase II trial of UR-63325 for allergic respiratory diseases

Concert Pharma patents new PEGylated azapeptide derivatives

Amgen identifies novel inhibitors of PI3K-alpha and/or mTOR

SciClone stops development of SCV-07 in chronic HCV infection based on phase IIb data

Provectus begins phase IIc trial of PH-10 in psoriasis

Jennerex and Transgene begin JX-594 trial in metastatic colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...